Table 3.
Mean (95% confidence interval) percentage inhibition of cytokine-induced STAT phosphorylation by tofacitinib in different cell populations at three months compared to baseline.
| Cytokine | JAKs | STAT | Percentage inhibition in different cell types | |||
|---|---|---|---|---|---|---|
| Monocytes | CD4+ T cells | CD4- T cells | B cells | |||
| IFN-γ | JAK1/2 | pSTAT1 | 34 (22;45) | 49 (40;58) | 58 (45;68) | |
| IFN-α | JAK1/TYK2 | pSTAT1 | 34 (7;54) | 50 (35;63) | 43 (31;56) | 30 (0.4;52) |
| IFN-α | JAK1/TYK2 | pSTAT4 | 45 (34;56) | 45 (34;56) | ||
| IL-2 | JAK1/3 | pSTAT5 | 60 (50;69) | 54 (44;64) | ||
| IL-4 | JAK1/3 | pSTAT6 | 25 (14;36) | 53 (44;61) | 73 (65;80) | 25 (3;52) |
| IL-7 | JAK1/3 | pSTAT5 | 47 (37;57) | 47 (25;63) | ||
| IL-15 | JAK1/3 | pSTAT5 | 55 (43;62) | 40 (29;50) | ||
| IL-21 | JAK1/3 | pSTAT3 | 55 (47;62) | 60 (53;67) | 42 (33;53) | |
| IL-6 | JAK1/2/TYK2 | pSTAT1 | 29 (18;39) | 41 (31;51) | ||
| IL-6 | JAK1/2/TYK2 | pSTAT3 | 12 (-30;45) | 42 (27;57) | 22 (9;35) | |
| IL-10 | JAK1/TYK2 | pSTAT3 | 10 (-1;21) | 19 (12;26) | 19(10;27) | 43 (28;56) |
Results with percentages ≥ 50 are shown in bold. Spaces left empty denote the cases in which the stimulated phosphorylation level does not differ from the constitutive level. JAK proteins involved in each cytokine signaling pathway studied are presented in the Table.
IFN, interferon; IL, interleukin; JAK, Janus kinase; (p)STAT, (phosphorylated) signal transducer and activator of transcription; TYK2, tyrosine kinase 2.